GlassScriptPhysician profile
Michael Nathan Cohen
NPI 1699038935
$13,134.43
in general payments reported to CMS, 2019-2025
11 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,229 · 2021: $1,765 · 2022: $3,447 · 2023: $85.13 · 2024: $249 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504 · Consulting Fee: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.47 |
| Consulting Fee | $189.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,566.15 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $3,767.94 | 2022-2025 | Syfovre |
| Alimera Sciences, INC. | $1,293.95 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $148.72 | 2025 | Acthar |
| Abbott Laboratories | $113.86 | 2019 | |
| Alcon Vision LLC | $105.02 | 2023-2025 | Clareon, Argos, Unity |
| Amgen INC. | $92.19 | 2024 | |
| Boston Scientific Corporation | $26.60 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $20.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.